12/20/2013 7:33:15 AM
The drug company AstraZeneca PLC lost a bid on Thursday to defend its widely used heartburn drug Nexium when an appeals court ruled that a new drug from Hanmi Pharmaceuticals did not infringe on Nexium patents. The U.S. Court of Appeals for the Federal Circuit upheld a lower court's ruling that Hanmi did not infringe on AstraZeneca's patent since the South Korean company uses different salts in making its products. The Federal Circuit issued an injunction against the Hanmi drug in August, but lifted it in September, AstraZeneca said earlier this week. Hanmi has won FDA approval for the drug, AstraZeneca said.
Help employers find you! Check out all the jobs and post your resume.
comments powered by